Galectin Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.
Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination. Galectin Therapeutics collaborates with academic institutions and clinical research organizations to advance its programs, conducting trials across the United States and select international sites. The company’s research builds on academic insights into carbohydrate-binding proteins and their role in cellular signaling pathways.
Galectin Therapeutics’ scientific platform is designed to selectively bind and inhibit galectin-3, a protein known to drive fibrosis through the activation of stellate cells and the accumulation of extracellular matrix. Belapectin has received regulatory attention for its potential to address unmet needs in NASH with advanced fibrosis, and the company continues to generate data on safety, efficacy and biomarker effects to support potential registration pathways.
Under the leadership of President and Chief Executive Officer Peter G. Traber, M.D., Galectin Therapeutics aims to translate its proprietary galectin-inhibitor technology into effective treatments for patients with severe fibrotic and oncology disorders. The company remains committed to leveraging its specialized expertise in galectin biology to address challenging disease areas with significant unmet medical need.
AI Generated. May Contain Errors.
